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Abstract 
Phase II enzymes play an important role in the biotransformation of endogenous compounds and xenobiotics to 
more easily excretable forms as well as in the metabolic inactivation of pharmacologically active substances. The 
purpose of phase II biotransformation is to perform conjugating reactions. These include glucuronidation, sulfation, 
methylation, acetylation, glutathione, and amino acid conjugation. In general, the respective conjugates are more 
hydrophilic than the parent compounds. Polymorphism in Phase II drug metabolism enzymes may have role in 
diseases, cancer, and others. This review discuss brief about polymorphism in Phase II drug metabolism enzyme. 
[JuKe Unila 2014; 4(8):254-268] 
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Introduction 
There are four discrete processes 
in the pharmacokinetic phase during the 
biological disposition of a drug (or other 
xenobiotic), namely its absorption, 
distribution, metabolism and excretion 
– the ADME concept.
1
 
Drugs are introduced into the 
body by several routes. They may be 
taken by mouth (orally); given by 
injection into a vein (intravenously), into 
a muscle (intramuscularly), into the 
space around the spinal cord 
(intrathecally), or beneath the skin 
(subcutaneously); placed under the 
tongue (sublingually); inserted in the 
rectum (rectally) or vagina (vaginally); 
instilled in the eye (by the ocular route); 
sprayed into the nose and absorbed 
through the nasal membranes (nasally); 
breathed into the lungs, usually through 
the mouth (by inhalation); applied to 
the skin (cutaneously) for a local 
(topical) or bodywide (systemic) effect; 
or delivered through the skin by a patch 
(transdermally) for a systemic effect. 
Each route has specific purposes, 
advantages, and disadvantages.
1
 
After the drug is absorbed, it is 
then distributed to various organs of the 
body. Distribution is influenced by how 
well each organ is supplied by blood, 
organ size, binding of the drug to 
various components of blood and 
tissues, and permeability of tissue 
membranes. The more fat-soluble a 
drug is, the higher its ability to cross the 
cell membrane. The blood-brain-barrier 
restricts passage of drugs from the 
blood into the central nervous system 
and cerebrospinal fluid. Protein binding 
(attachment of the drug to blood 
proteins) is an important factor 
influencing drug distribution. Many 
drugs are bound to blood proteins such 
as serum albumin (the main blood 
protein) and are not available as active 
drugs.
1 
By the early part of the 20
th
 
centurythe major drug metabolizing 
reactions had been identified. A unifying 
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theory on the role of metabolism was 
developed by John Paxson Sherwin.
2
 
Xenobiotic metabolizing 
enzymes have historically been grouped 
into the phase 1 reactions, in which 
enzymes carry out oxidation, reduction, 
or hydrolytic reactions, and the phase 2 
reactions, in which enzymes form a 
conjugate of the substrate (the phase 1 
product).
3 
Phase II biotransformation 
reactions that a drug or its metabolite 
typically undergo. In these so-called 
‘conjugation reactions’, mediated by the 
appropriate enzymes, the drug becomes 
linked to an endogenous moiety 
through one or more functional groups, 
that may either be present on the 
parent drug, or which may have resulted 
from a phase I reaction of oxidation, 
reduction or hydrolysis. A characteristic 
of most conjugation reactions is the 
replacement of a hydrogen atom 
present in a hydroxyl, amino or carboxyl 
group, by the conjugating agent. In 
general, the resulting conjugated 
metabolites have no pharmacological 
activity, are highly water-soluble and 
therefore subsequently readily excreted 
in the urine. These reactions are usually 
considered as detoxication reactions, 
but in certain cases, toxication has been 
recorded, and examples of both are 
treated below. Major phase II reactions 
include glucuronidation, sulphation, 
acetylation, and conjugation with 
glutathione or amino acids.
1
 
Parent drugs or their phase I 
metabolites that contain suitable 
chemical groups often undergo coupling 
or conjugation reactions with an 
endogenous substance to yield drug 
conjugates (Table 1). In general, 
conjugates are polar molecules that are 
readily excreted and often inactive. 
Conjugate formation involves high-
energy intermediates and specific 
transfer enzymes. Such enzymes 
(transferases) may be located in 
microsomes or in the cytosol. Of these, 
uridine 5'-dphosphate[UDP]-
glucuronosyl transferases [UGTs] are the 
most dominant enzymes. These 
microsomal enzymes catalyze the 
coupling of an activated endogenous 
substance (such as the UDP derivative
 
 
 
Figure 1. Phase I and II reaction  
(Source: Katzung BG, Masters SB, and Trevor AJ; Basic and Clinical Pharmacology 11
th
 ed., 2005) 
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of glucuronic acid) with a drug (or 
endogenous compound such as bilirubin, 
the end product of heme metabolism). 
Nineteen UGT genes (UGTA1and UGT2) 
encode UGT proteins involved in the 
metabolism of drugs and xenobiotics. 
Similarly, 11 human sulfo transferases 
[SULTs] catalyze the sulfation of 
substrates using 3'-phosphoadenosine 
5'-phosphosulfate [PAPS] as the 
endogenous sulfate donor. Cytosolic 
and microsomal glutathione [GSH] 
transferases [GSTs] are also engaged in 
the metabolism of drugs and 
xenobiotics, and in that of leukotrienes 
and prostaglandins, respectively. 
Chemicals containing an aromatic amine 
or a hydrazine moiety (eg, isoniazid) are 
substrates of cytosolic N-acetyl 
transferases [NATs], encoded by NAT1 
and NAT2 genes, which utilize acetyl 
CoA as the endogenous cofactor.
4 
S-adenosyl-L-methionine[SAMe; 
AdoMet]-mediated O-, N-, and S-
methylation of drugs and xenobiotics 
bymethyltransferases [MTs] also occurs. 
Finally, endobiotic, drug, and xenobiotic 
epoxides generated via P450-catalyzed 
oxidations can also be hydrolyzed by 
microsomal or cytosolic epoxide 
hydrolases [EHs].  
Conjugation of an activated drug 
such as the S-CoA derivative of benzoic 
acid, with an endogenous substrate, 
such as glycine, also occurs. Because the 
endogenous substrates originate in the 
diet, nutrition plays a critical role in the 
regulation of drug conjugations 
process.
4
 Phase II reactions are 
relatively faster than P450-catalyzed 
reactions, thus effectively accelerating 
drug biotransformation process. 
Drug conjugations were once 
believed to represent terminal 
inactivation events and as such have 
been viewed as "true detoxification" 
reactions. However, this concept must 
be modified, because it is now known 
that certain conjugation reactions (acyl 
glucuronidation of nonsteroidal anti-
inflammatory drugs, O-sulfation of N-
hydroxyacetylaminofluorene, and N-
acetylation of isoniazid) may lead to the 
formation of reactive species 
responsible for the toxicity of the drugs. 
Furthermore, sulfation is known to 
activate the orally active pro drug 
minoxidil into a very efficacious 
vasodilator, and morphine-6-
glucuronide is more potent than 
morphine itself.
4
 
The term genetic polymorphism 
defines monogenic traits that exist in 
the normal population in at least two 
phenotypes, neither of which is rare. 
Genetic polymorphisms in drug 
metabolism are common occurrences. 
Mutations in the genes for numerous 
drug-metabolizing enzymes cause 
enzyme variants with higher or lower 
activity or lead to the partial or total 
absence of an enzyme protein. Genetic 
polymorphisms have been described for 
a wide variety of drug and xenobiotic 
metabolizing enzymes. Many of these 
variations were first identified by the 
occurrence of adverse reactions after 
normal doses of drugs inpatients or 
volunteers. The association between 
decreased drug clearance and 
decreased activity of a drug-
metabolizing enzyme, the inherited 
nature of the deficiency, and its 
frequency and clinical importance was 
then evaluated. Phenotyping methods 
involving administration of probe drugs 
and measurement of metabolites in 
body fluids or determination of enzyme 
activity in families and populations were 
used for this purpose.                                
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During the past 10 years, several of 
these polymorphisms have been studied 
at the protein and gene                                        
level, and simple DNA tests have been 
developed to predict the                      
phenotype.
5
 
 
Table 1. Phase II reaction* 
Type of 
Conjugation 
Endogenous Reactant Transferase 
(Location) 
Types of 
Substrates 
Examples 
Glucuronidation UDP glucuronic acid UDP 
glucuronosyl 
transferase 
(microsomes) 
Phenols, alcohols, 
carboxylic acids, 
hydroxlamines, 
sulfonamides 
Nitrophenol, 
morphine, 
acetamoniphen, 
diazepam, N-
hydroxy dapsone, 
sulfathiazole, 
meprobamate, 
digitoxin, digoxin 
Acetylation Acetyl-CoA N-Acetyl 
transferase 
(cytosol) 
Amines Sulfonamides, 
isoniazid, 
clonazepam, 
dapsone, 
mescaline 
Glutathione 
conjugation 
Glutathione (GSH) GSH-S-
transferase 
(cytosol, 
microsomes) 
Epoxides, arene 
oxides, nitro 
groups, 
hydroxylamines 
Acetaminophen, 
ethacrynicacid, 
bromobenzene 
Glycine 
conjugation 
Glycine Acyl-CoA 
glycine 
transferase 
(mitochondria) 
Acyl-CoA 
derivatives of 
carboxylic acids 
Salycylic acid, 
benzoic acid, 
nicotinic acid, 
cinnamic acid, 
cholic acid, 
deoxycholic acid 
Sulfation Phosphoadenosylpho
sphosulfate 
Sulfo 
transferase 
(cytosol) 
Phenols, alcohols, 
aromatic amines 
Estrone, aniline, 
phenol, 3-hydroxy-
coumarin, 
acetaminophen, 
methyldopa 
Methylation S-adenosylmethionine Transmethylas
es (cytosol) 
Cathecolamine, 
phenols, amines 
Dopamine, 
ephinephrine, 
pyridine, 
histamine, 
thiouracil 
Water 
conjugation 
Water Epoxide 
hydrolase 
(microsomes) 
Arene oxides, cis-
disubstituted and 
mono-substituted 
oxiranes 
Benzopyrene, 7,8-
epoxide, styrene 
1,2-oxyde, 
carbamazepine 
epoxide 
  (cytosol) Alkene oxides, 
fatty acid 
epoxides 
Leukotriene A4 
Data source from Katzung BG et al.
4
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Discussion 
All enzymes involved in the 
metabolism of drugs are regulated by 
genes and gene products. Because of 
evolutionary and environmental factors, 
there is a remarkable degree of genetic 
variability built into the population. 
Thus, the genetic factor represents an 
important source of inter individual 
variation in drug metabolism. Mutations 
in the gene for a drug-metabolizing 
enzyme result in enzyme variants with 
higher, lower, or no activity or may lead 
to a total absence of the enzyme. 
Therefore, it is not unusual to find a ten-
fold or as much as a 50-fold difference 
in the rate of drug metabolism among 
patients. With the technological 
breakthroughs in molecular biology, 
significant progress has been made in 
understanding the role of genetic 
polymorphisms in drug metabolism 
process.
6 
 
A. Glucuronidation 
Glucuronidation represents one 
of the most important phase II 
biotransformation reactions converting 
thousands of lipophilic endobiotics and 
xenobiotics (drugs, dietary plant 
constituents, etc.) and their phase I 
metabolites into hydrophilic and 
excretable conjugates. For many 
compounds such as plant constituents 
which already contain functional groups 
(-OH, -COOH, -SH, -NH2) glucuronidation 
represents the primary 
biotransformation reaction. 
Glucuronidation is catalysed by a 
supergene family of UDP-glucuronosyl 
transferases (UGTs) which are integral 
proteins of the membranes of the 
endoplasmic reticulum and the nuclear 
envelope. UGTs are present in many 
tissues of vertebrates (mammals, fish 
and- although no sequences have been 
published-in amphibian, reptiles and 
birs).
7
 
Conjugation reactions catalyzed 
by the super family of these enzymes 
serve as the most important 
detoxification pathway for broad 
spectrum of drugs, dietary chemicals, 
carcinogens and their oxidized 
metabolites, and other various 
environmental chemicals in all 
vertebrates. Furthermore, UGTs are 
involved in the regulation of several 
active endogenous compounds such as 
bile acids or hydroxysteroids due to 
their inactivation via glucuronidation.
8,9
 
In humans, almost 40–70% of 
clinically used drugs are subjected 
toglucuronidation.
10
 The mammalian  
UGT gene super family comprises of 117 
members. Four UGT families have been 
identified in humans: UGT1, UGT2 
involving UGT2A and UGT2B subfamily, 
UGT3 and UGT8. Enzymes included in 
the UGT1 and  UGT2 subfamily are 
responsible for the glucuronidation of 
exo– and endogenous compounds, 
whereas members of the UGT3 and 
UGT8 subfamilies have their distinct 
functions.
11
 
Recently, twenty-two human 
UGT proteins were identified: UGT1A1, 
1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9,1A10, 
2A1, 2A2, 2A3, 2B4, 2B7, 2B10, 2B11, 
2B15, 2B17, 2B28, 3A1, 3A2 and 8A1. 
Many of these forms, but not all, are 
shown to have broad tissue distribution 
with liver as a major location. The 
UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7 and 
2B15 enzymes are considered to be the 
most important human liver drug 
metabolising UGT forms. Several UGT 
forms are expressed mainly  in the 
gastrointestinal tract e.g. UGT1A7, 
UGT1A8 and UGT1A10. Intestinal UGTs 
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are presumed to be of particular 
importance in the first-pass metabolism 
of dietary supplements and drugs. They 
can also influence their oral 
bioavailability. Kidney, brain, and 
placenta also exert glucuronidation 
activity.
8,11-17
 
In steatosis mouse models, UGT 
induction was accompanied by 
increased aryl hydrocarbon receptor, 
constitutive androstane receptor (CAR), 
peroxisome proliferator-activated 
receptor (PPAR)-γ, pregnane X receptor, 
nuclear factor (erythroid-derived 2)-
like2 (Nrf2), and peroxisome 
proliferator-activated receptor-γ 
coactivator-1αmRNA expression. In 
addition, fasting increased CAR, PPAR, 
and Nrf2 binding activity. The work 
points to hepatic triglyceride 
concentrations corresponding with 
nuclear receptor and UGT expression.
18 
Some polymorphisms in 
glucuronidation had been known. Sex 
steroids are metabolized to less active 
compounds by glucuronidation, 
catalyzed by UDP-glucuronosyl 
transferases (UGT) and sulfation, 
catalyzed by sulfotransferases (SULT). 
Women with the UGT1A1(TA7/TA7) 
genotype had 25% lower mean estradiol 
(E2) concentrations compared to the 
wild type (TA6/TA6).
19  
The mutations in UGT1A1 gene 
result in several syndromes connected 
with decreased bilirubin detoxification 
capacity of UGT1A1. More than 50 
mutations of UGT1A1 causing Crigler–
Najjar syndrome type I and type II.
20
 
Patients suffering from type I, also 
called congenital familial nonhemolytic 
jaundice with kernicterus, completely 
lack the UGT1A1 enzymatic activity 
resulting in toxic  effects of bilirubin on 
the central nervous system. The most 
common deficiency of UGT1A1 enzyme 
is Gilbert‘s syndrome. 2–12% of the 
population suffer from this benign 
disorder characterized by intermittent 
unconjugated hyper-bilirubinemia. In 
most cases, this syndrome is caused by a 
mutation in the promotor region of 
UGT1A1 gene.
21
 Increased toxicity of a 
pharmacologically active metabolite of 
irinotecan (SN–38) has been described 
in patients suffering from Gilbert’s 
syndrome as UGT1A1 is the main  
enzyme responsible for the formation of 
the inactive SN–38 glucuronide.
22 
The 
genetic variability in the UGT1 or UGT2 
gene families was also suggested to 
alter risk of cancer either as a result of 
decreased inactivation of hormones 
such as estrogens or due to reduced 
detoxification of environmental 
carcinogens and their reactive 
metabolites.
23 
 
B. Sulfation 
Sulfotransferases are a 
supergene family of enzymes that 
catalyse the conjugation of 3’ 
phosphoadenosine 5’-phosphosulphate 
(PAPS) with an O-, N- or S- acceptor 
group of an appropriate molecule. In 
general, O-sulfation represents the 
dominant cellular sulfonation reaction. 
N-sulfation is a crucial reaction in the 
modification of carbohydrate chains in 
macromolecules such as heparin and 
heparan sulfate, common components 
of proteoglycan.
24
 N-Sulfoconjugation is 
also involved in the metabolism of 
xenobiotics such as quinolones and 
amino drugs.
25 
The PAPS is a universal 
sulfate donor molecule required for all 
sulfonation reactions and it can be 
synthesized by all tissues in mammals.
26
 
 
Muhammad Ricky Ramadhian | Inherited Variation in Drugs Effect Independent in Pharmacokinetic 
JUKE | Volume 4 Nomor 8 | September 2014                                                                                                                      260 
Table 2. Examples of Xenobiotics and Endogenous Compounds That Undergo Sulfate Conjugation 
Functional Group Example 
Primary alcohol Chloramphenicol, ethanol, hydroxymethyl polycyclic aromatic 
hydrocarbons, polyethylene glycols 
Secondary alcohol Bile acids, 2-butanol, cholesterol, dehydroepiandrosterone, doxaminol 
Phenol  Acetaminophen, estrone, ethinylestradiol, naphthol, pentachlorophenol, 
phenol, picenadol, salicylamide, trimetrexate 
Catechol Dopamine, ellagic acid, -methyl-DOPA 
N-oxide  Minoxidil 
Aliphatic amine 2-Amino-3,8-dimethylimidazo[4,5,-f]-quinoxaline (MeIQx)*  
  2-Amino-3-methylinidazo-[4,5-f]-quinoline (IQ)*  
  2-Cyanoethyl-N-hydroxythioacetamide, despramine  
Aromatic amine 2-Aminonaphthalene, aniline 
Aromatic hydroxylamine N-hydroxy-2-aminonaphthalene  
Aromatic hydroxyamide N-hydroxy-2acetylaminofluorene 
  
 
*Amino acid pyrolysis products 
 
To date, two large groups of SULTs have 
been identified. The  first group includes 
membrane–bound enzymes with no 
demonstrated xenobiotic–metabolising 
activity. These enzymes are localized in 
the Golgi apparatus and they are 
involved in metabolism of endogenous 
peptides, proteins, glycosaminoglycans, 
and lipids.
24
 
Second group, cytosolic SULTs 
are presumed to play a crucial role in 
the detoxification processes occurring in 
the developing human fetus since no 
UGTs transcripts have been detected in 
fetal liver at 20 weeks of gestation.
27 
Sulfonation is generally described as a 
detoxification pathway for many 
xenobiotics. Furthermore, the role of 
sulfotransferases in the activation of 
various procarcinogens and 
promutagens was confirmed.
28
 
We focus only in cytosolic 
sulfotransferases.The super family of 
cytosolic sulfotransferases is 
subsequently divided into families and 
subfamilies according to the amino acid 
sequence identity among individual 
SULTs. In detail, members of one SULTs 
family share at least 45% amino acid 
sequence identity, whereas SULTs 
subfamily involves individual members 
with at least 60% identity. There are 
four human SULT families, SULT1, SULT2, 
SULT4 and SULT6, have been identified. 
These SULT families include at least 13 
different members. The SULT1 family 
comprises of 9 members divided into 4 
subfamilies (1A1, 1A2,  1A3, 1A4, 1B1, 
1C1, 1C2, 1C3 and 1E1). SULT2A 
(SULT2A1) and SULT2B (SULT2B1a and 
SULT2B1b) belong to SULT2 family. The 
SULT4A1 and SULT6B1 are the only 
members of the SULT4 and SULT6 family, 
respectively.
29
 Cytosolic sulfo-
transferases exert relatively broad tissue 
distribution. 
Genetic polymorphism was 
detected in many SULT forms such as 
the SULT1A1, SULT1A3, SULT1C2, 
SULT2A1, SULT2A3 and SULT2B1 
enzyme.
29 
Single nucleotide 
polymorphism in the  SULT1A1  gene 
leading to an Arg213 → His amino acid 
substitution is relatively frequent in the 
Caucasian population (25.4–36.5%).
30 
This mutation results in a variation  of 
SULT1A1 thermal stability and 
enzymatic activity. SULT1A1 
polymorphism might play role in the 
pathophysiology of lung cancer, 
urothelial carcinoma, and meningiomal 
brain tumors.
31-33
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C. Glutathion 
The glutathione S-
transferasesare capable of catalyzing a 
seemingly protean spectrum of  
reactions; they are widely distributed 
and are present at high concentrations 
in the cytosol. The overall hypothesis for 
what follows is based on the ability of 
these proteins to bind hydrophobic 
compounds and, specifically, to increase 
the nucleophilicity of the sulfhydryl 
group of  glutathione (GSH). These  two  
attributes of the glutathione 
transferases are sufficient to account for  
the extensive list  of  titles  that have  
been bestowed  on them.  In current  
usage  are the following terms:  
glutathione S-alkyltransferase, 
glutathione S-aryl-transferase, 
glutathione S-aralkyltransferase, 
glutathione S-alkenetransferase,  
glutathione  S-epoxide transferase,  
nitrate  ester  reductase, steroid 
isomerase,  A'-3-ketosteroid  isomerase, 
and  ligandin. With  the exception of the 
steroid-designated enzymes, all these 
activities should now be  identified 
solely as  glutathione S-transferase. 
(34)
 
Glutathione exists in the cell as 
oxidized (GSSG) or reduced (GSH),and 
the ratio of GSH: GSSG is critical in 
maintaining acellular environment in 
the reduced state. In addition to 
affecting xenobiotic conjugation with 
GSH, a severereduction in GSH content 
can predispose cells to oxidative 
damage, a state that has been linked to 
a number ofhuman health issues.
35
 
 Two distinct super families of 
GSTs have been described. One 
comprises soluble dimeric enzymes that 
areinvolved in biotransformation of 
toxic xenobiotics and endobiotics.The 
soluble GST super family is subdivided 
into eight separate classes designated 
Alpha, Kappa, Mu, Pi, Sigma, Theta, Zeta 
and Omega. Soluble GSTs have been 
described mainly in cytoplasm but they 
are also presented in nucleus, 
mitochondria and peroxisomes.
36,37
 The 
other superamily of GSTs designated as 
MAPEG (membrane-associated proteins 
in eicosanoid and glutathione 
metabolism), probably with trimeric 
structure, is involved in arachidonic acid 
metabolism.
38,39 
 Members of both GST 
families exhibit selenium-independent 
glutathione peroxidase activity. 
Several types of allelic variations 
have been identified in the class Alpha, 
Mu, Pi, Theta GST gene families. 
Individuals lacking GST-M1, GST-T1 and 
GST-P1 genes have a higher incidence of 
bladder, breast, colorectal, head/neck 
and lung cancer. Loss of these genes 
have also been found to increase 
susceptibility to asthma and allergies, 
atherosclerosis and rheumatoid 
arthritis.
40,41
 Little is known about 
polymorphism in membrane-associated 
proteins in eicosanoid and glutathione 
metabolism genes. Iida et al. described 
single-nucleotide polymorphism of 
MGST1 (a member of MAPEG) in 
healthy Japanese volunteers.
42
 
 
D. Acetylation 
By now, you will hopefully be 
familiar with the central idea that 
biotransformation increases water 
solubility at the expense of lipid 
solubility. Acetylation is generally 
classified as a Phase II process, although 
it appears to be rather contradictory as 
acetylated metabolites are less water-
soluble than the parent drug; indeed, 
this often makes acetylated metabolites 
difficult to eliminate in urine. In 
extreme , acetylated metabolites of 
some old sulphonamides were so poorly 
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water-soluble that they crystallized 
(painfully) in the patient’s kidneys. You 
may be wondering what 
acetyltransferases are actually for, since 
they do not at fi  rst appear to 
contribute positively to the clearance of 
their substrates. There are a number of 
acetyltransferase gene families found in 
most cells and they have a large number 
of functions connected with cell 
homeostasis; for example, histone 
acetyl transferases (HATs) regulate DNA 
transcription through activating histone 
proteins by acetylating them, whilst 
some hormones such as melatonin are 
regulated through acetyltransferases. 
Although most metabolic reactions are 
to some extent reversible, acetylation is 
much more reversible than most. 
Indeed, there are many of these 
enzymes that are predominantly 
deacetylases, as well as acetylases. 
Many acetylated molecules can act as  
‘on’ and‘off ’  switches in the regulation 
of the functions of nuclear receptor 
systems. The acetyl transferases 
relevant to human drug metabolism 
include two families of genes which are 
expressed, N-acetyltransferase 1 (NAT-
1) and N-acetyltransferase 2 (NAT-2). 
These enzymes use acetyl Co enzyme A 
as a cofactor to acetylate their 
substrates by using whatis known as a 
double displacement (ping-pong) 
mechanism. There are two sequential 
steps to the reaction: firstly, the acetyl 
group is moved from acetyl CoA to form 
an acetylated enzyme intermediate, 
then the substrate is acetylated and CoA 
is released. Iodacetate andN-
ethylmaleide are irreversible inhibitors 
of the process, whilst reversible 
inhibitors (salicylamide) are similar in 
structure to the substrates. NAT-1 is 
found in many tissues, particularly in the 
colon, but also in erythrocytes. NAT-1 
expression was thought to be fairly 
constant through human populations, 
but recent studies have shown that 
there is at least a two-fold difference in 
some populations and it is believed that 
NAT-1 may be inducible in response to 
certain xenobiotic and endogenous 
substrates.
43
 
Human NAT1 and human NAT2 
have different substrate specificities. 
Typical specific substrates for human 
NAT1 are: p-aminobenzoic acid (PABA), 
p-aminosalicylic acid and p-
aminobenzylglutamate. Sulfame-thazine 
is used as a NAT2-selective 
substrate.Human NAT2 provides a major 
route for detoxification of drugs such as 
isoniazid (antituberculoticdrug), 
hydralazine (antihypertensive drug) and 
sulphonamides (antibacterial drugs).
44,45
 
Variation among the human 
population in the ability to acetylate 
drugs has been known sincethe 
observations on individual variations in 
isoniazid toxicity in the 1950s. The 
genetic basis forthis was soon 
appreciated and has come to be known 
as the N-acetylation polymorphism. 
Acetylationwas variable in the human 
population, that it is inherited, and the 
molecular basis for this phenomenon. 
Since accurate determination of 
acetylator phenotype is critical to 
testing a number ofimportant 
hypotheses, including the link between 
disease risk and acetylator phenotype, 
limitations and potential problems with 
various methods of phenotype 
determination are discussed.
46 
N–acetylation polymorphism 
represents one of the oldest and most 
intensively studied pharmacogenetic 
traits and  refers to hereditary 
differences concerning the acetylation 
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of drugs and toxicants. The genetic 
polymorphism in NAT activity was first 
recognised in tuberculosis patients 
treated with isoniazid, which is 
metabolised principally by N–
acetylation. The polymorphism causes 
individual differences in the rate of 
metabolism of this drug. Individuals 
with a faster rate are  called rapid 
acetylators  and individuals with a 
slower rate are called slow acetylators. 
Rapid acetylators were competent in 
isoniazid acetylation but the drug was 
cleared less efficiently in the slow 
acetylator group, which resulted in 
elevated serum concentration and led 
to adverse neurologic side effects due to 
an accumulation of unmetabolized 
drug.
47
 Consistent with the toxicity of 
isoniazid in slow acetylators, there is an 
increased incidence of other drug 
toxicities in subjects carrying defective  
NAT2 alleles, such as lupus 
erythematosus in patients treated with 
hydralazine or procainamide, and 
haemolytic anemia and inflammatory 
bowel disease after treatment with 
sulfasalazine
48,49
. The high frequency of 
the NAT2 and also NAT1 acetylation 
polymorphism in human population 
together with ubiquitous exposure to 
aromatic and heterocyclic amines 
suggest that NAT1 and NAT2 acetylator 
genotypes are important modifiers of 
human cancer susceptibility. Many 
studies suggested a relationship 
between acetylation phenotypes (in 
particular, arising from NAT2 genotypes) 
and the risk of various cancer                        
including colorectal, liver, breast, 
prostate, head and neck,                         
and other disease conditions               
such as birth defects
 
or 
neurodegenerative and autoimmune 
diseases.
50-52
 
E. Methylation  
Methylation reactions are mainly 
involved with endogenous compound 
metabolism but some drugs may be 
methylated by non-specific 
methyltransferases foundin lung, and by 
the physiological methyltransferases. A 
list of the methyltransferases and their 
substrates is given in Table 3. 
The cofactor, S-adenosyl 
methionine (SAM), is required to form 
methylconjugates and is produced from 
L-methionine and ATP under the 
influence ofthe enzyme, L-methionine 
adenosyltransferase. SAM can also be 
considered as a high-energy 
intermediate. The non-specific N-
methyltransferase found in the lung can 
reverse the N-demethylation reactions 
of phase 1 metabolism but most ofthe 
other methyltransferases are specific for 
endogenous compounds except the S-
methyltransferase that is foundin the 
microsomal fraction and which will 
methylate many thiols such as thiouracil.  
In general, unlike other 
conjugation reactions, methylation 
leads to a less polar product and thus 
hinders excretion of the drug.
53 
The 
methyl transferases represent a 
relatively large number of enzymes that 
utilize the cofactor, S-adenosyl-L-
methionine, in which the methyl group 
is bound to a positively charged sulfur, 
to transfer a methyl group to an oxygen, 
sulfur, or nitrogen atom in 
anappropriate substrates.
54 
 
E.1. S–methylation  
Thiol methylation is important in 
the metabolism of many sulfhydryl 
drugs. Human tissues contain two 
separate genetically regulated enzymes 
that can catalyze thiol S–methylation. 
Thiolmethyltransferase (TMT) is a 
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membrane–bound enzyme that 
preferentially catalyzes the S–
methylation of aliphatic sulfhydryl 
compounds such as captopril and D–
penicillamine, whereas  thiopurine S–
methyltransferase (TPMT) is a 
cytoplasmic enzyme that preferentially 
catalyzes the S–methylation of aromatic 
and heterocyclic sulfhydryl compounds 
including anti cancer and 
immunosuppressive thiopurines  such as 
6–mercaptopurine, 6–thioguanine, and 
azathioprine. Thiopurine drugs have a 
relatively narrow therapeutic index and 
are capable of causing life–threatening 
toxicity, most often myelosuppression.
55 
TPMT genetic polymorphism represents 
a striking example of the clinical 
importance of pharmacogenetics.  
In 2010, 29 different variant  
TPMT alleles have been described and 
this may be associated with large 
interindividual variations in thiopurine 
drug toxicity and therapeutic efficacy.
56
 
Allele frequencies for genetic 
polymorphism are such that ~1 in 300 
Caucasians is homozygous for a 
defective allele or alleles for the trait of 
very low activity, ~11% of people are 
heterozygous and have intermediate 
activity.  
Subjects homozygous for low 
TPMT activity have a high risk of 
myelosuppression after treatment with 
standard dose of azathioprine. Generally, 
TPMT–deficient patients (homozygous 
mutant) can be treated with 6–10% of 
the standard dose of thiopurines.
57
 
TPMT shows the highest level of 
expression  in liver and kidney and the 
physiological role of this enzyme, 
despite extensive investigation, remains 
unclear. 
 
E.2. CathecolO-Methyl Transferase 
(COMT) 
Catechol O-methyltransferase is 
responsible for transfer of a methyl 
group from S-adenosylmethionine to 
catecholamines. This O-methylation 
results in one of the major degradative 
pathways of the catecholamine 
transmitters. COMT is an enzyme that 
plays a key role in the modulation of 
catechol-dependent functions such as 
cognition, cardiovascular function and 
pain processing. COMT substrates 
include not only neurotransmitters 
 
Tabel 3. The methyltransferases 
 
Source: Gibson GG et al.
53
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and dopamine but also drugs having a 
catechol structure used in the 
treatment of hypertension, asthma and 
Parkinson’s disease.
58
 COMT was first 
described by Axelrod in 1957. 
COMT is an intracellular enzyme 
located in the post-synaptic neuron. 
COMT is presented in mammalian cells 
in two forms: in a cytoplasmic soluble 
form (S-COMT) and a membrane-bound 
form (MB-COMT) located in the 
cytosolic side of the rough endoplasmic 
reticulum.
59
 
Primary structures of the two 
COMT forms are otherwise identical 
but differences between S-COMT and 
MB-COMT reside within the N-termini. 
The MB-COMT has an N-termini 
extension of about 50 amino acids. S-
COMT is expressed at higher levels in 
most tissues than MB-COMT. The 
highest COMT activities have been 
found in liver, kidney, intestine, and 
brain. S-COMT is predominantly 
expressed in peripheral tissues, while 
MB-COMT is mostly expressed in the 
brain. In the blood, COMT is found 
mainly in erythrocytes; in leukocytes its 
activity is low. 
A functional single nucleotide 
polymorphism of the gene for catechol-
O-methyl transferase (VAL 108/158 
MET) has been identified. The level of 
COMT enzymeactivity (low, 
intermediate and high levels) is 
genetically polymorphic in human red 
blood cells and liver. This 
polymorphism is due to a G-to-A 
transition at codon 158 (for MB-COMT) 
or codon 108 (for S-COMT) of the 
COMT gene and results in the 
substitution of the amino acid valine 
for methionine causing a decrease in 
the activity level of the COMT enzyme 3 
to 4 fold. 
Functional polymorphism in the 
COMT gene (VAL 108/158 MET) has 
been examined in relationship to a 
number of neurological disorders 
involving the noradrenergic or 
dopaminergic systems, such as 
schizophrenia
, 
and Parkinson's disease. 
It has been suggested that a common 
functional genetic polymorphism in the 
COMT gene may contribute to the 
etiology of alcoholism. The COMT 
polymorphism contributes significantly 
to the development of late-onset (≥25 
years) alcoholism. An association of 
COMT low activity with early-onset 
(<25 years) alcoholism has been 
demonstrated as well. 
 
Conclusion 
Phase II enzymes play an 
important role in the detoxification of 
various xenobiotics. They significantly 
contribute to maintaining of 
homeostasis by binding, transport or 
inactivation of biologically active 
compounds such as hormones, bile 
acids, or other mediators. In contrast to 
their beneficial effects, these enzymes 
also participate in formation of reactive 
intermediates of various compounds. 
The most–discussed example of 
toxification reactions is the conjugation 
of N–hydroxy aromaticamines. These 
compounds undergo activation to toxic 
metabolites by numerous reactions, 
including N–glucuronidation by UGTs, 
O–acetylation by NATs, O–sulfonation 
by SULTs, and conjugation with amino  
acids by aminoacyl–tRNA–synthetase. 
The newly formed reactive electrophilic 
nitrenium and carbonium ions can act 
as carcinogens and mutagens due to 
covalent binding to DNA or to other 
biomolecules. Genetic polymorphisms 
of Phase II enzymes is another 
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noteworthy issue. Impaired 
metabolism of drugs due to genetically 
based dysfunction of competent 
enzymes may lead to manifestation of 
toxic effects of clinically used drugs. 
Moreover, it is evident that genetic 
polymorphisms in these enzymes are 
responsible for the developement of a 
number of neurological disorders or 
cancers. In conclusion, Phase II 
enzymes are an interesting  research 
field since they play an essential role in 
the metabolism of hundreds of foreign 
compounds as well as in regulation of 
metabolism and disposition of various 
endogenous biologically active 
substances and thus maintaining 
homeostasis in the human body.  
 
Daftar Pustaka 
1. Ionescu C, Caira MR. Chapter I Drug Metabolism 
In Context. In Drug Metabolism Current 
Concepts. Springer; 2005. 
2. Pearson PG, Wienkers LC. Handbook ofdrug 
metabolism. 2nd ed. USA: Informa Healtcare; 
2009. 
3. Brunton LL, Parker KL, Buxton ILO, Blumenthal 
DK. Drug Metabolism. In Goodman & Gilman's 
The Pharmacological Basis of Therapeutics. 11
th
 
Edition. New York: McGrawHill,Inc; 2007. 
4. Katzung B, Masters S, Trevor A. Basic and Clinical 
Pharmacology 11
th
. New York : McGraw-Hill 
Companies,Inc; 2005. 
5. Meyer UA, Zanger UM. Molecular Mechanisms 
of Genetic Polymorphisms of Drug Metabolism 
Annu Rev Pharmacol Toxicol. 1997; 37:269–96. 
6. Lin JH, Lu AYH. Role of Pharmacokinetics and 
Metabolism in Drug Discovery and Development. 
Pharmacological Review. 1997; 49(4):403-49 
7. Bock KW. UDP-Glucuronyltransferase. In 
Ioannides C. Enzymes Systems That Metabolise 
Drugs and Other Xenobiotics. New Jersey: John 
Wiley & Sons Ltd; 2001. 
8. Miners JO., Knights KM, HoustonJB, McKenzie PI. 
In vitro-in vivo correlation for drugs and other 
compounds eliminated by glucuronidation in 
humans: pitfalls and promises. Biochem Pharm. 
2006; 71(11):1531–9. 
9. Kiang TK, Ensom MH, Chang TK. UDP–
glucuronosyltransferases and clinical drug–drug 
interactions. Pharmacology& Therapeutics. 
2005; 106(1):97–132. 
10. Wells PG, Mackenzie PI, Chowdhury JR, 
Guillemette C, Gregory PA, Ishii Y, et al. Drug 
Metabolism and Disposition. Glucuronidation 
and the UDP–glucuronosyltransferases in health 
and disease. 2004; 23(3):281-90. 
11. Mackenzie PI, Rogers A, Treloar J, Jorgensen BR, 
Miners JO, Meech R. Identification of UDP 
glycosyltransferase 3A1 as a UDP N–
acetylglucosaminyltransferase. The Journal of 
Biological Chemistry. 2008; 283(52):36205–10. 
12. Court MH, Hazarika S, Krishnaswamy S, Finel M, 
Williams JA. Novel polymorphic human UDP-
glucuronosyltransferase (UGT)2A3: Cloning, 
functional characterization of enzyme variants, 
comparative tissue expression, and gene 
induction. Mol Pharmacol. 2008; 74(3):744-54. 
13. Patten CJ. New technologies for assessing UDP–
glucuronosyltransferase (UGT) metabolism in 
drug discovery and development. Drug Discovery 
Today: Technologies. 2006;  3(1):73–8. 
14. Sneitz N, Courth MH, Zhang X, Laajanen K, Yee 
KK, Dalton P, et al. Human UDP-
glucuronosyltransferase UGT2A2:cDNA 
construction, expression, and functional 
characterization in comparison with UGT2A1 and 
UGT2A3. Pharmacogenet Genomics. 2009; 
19(12):923-34. 
15. Sutherland L. The expression of UDP-
glucuronosyltransferases of the UGT1 family in 
human liver and kidney and in response to drugs. 
Biochem Pharmacol. 1993; 45(2):295–301. 
16. King CD, Rios GR, Assouline JA, Tephly TR. 
Expression of UDP-glucuronosyltransferases 
(UGTs) 2B7 and 1A6 in the human brain and 
identification of 5-hydroxytryptamine as a 
substrate. Arch Biochem Biophys. 1999; 
365(1):156–62. 
17. Collier AC. UDP-glucuronosyltransferase activity, 
expression and cellular localization in human 
placenta at term. Biochem Pharmacol. 2002; 
63(3):409–19. 
18. Xu J, Kulkarni SR, Li L, Slitt AL. UDP-
Glucuronosyltransferase Expression in Mouse 
Liver Is Increased in Obesity- and Fasting-
Induced Steatosis. Drug Metabolism and 
Disposition. 2012; 40(2):259-66. 
19. Yong M. Associations between polymorphisms in 
glucuronidation and sulfation enzymes and sex 
steroid concentrations in premenopausal women 
in the United States. J Steroid Biochem Mol Biol. 
2011; 124(1-2):10-8. 
20. Kadakol A, Ghosh SS, Sappal BS, Sharma G, 
Chowdhury JR, Chowdhury NR. Genetic lesions 
of bilirubin uridine–diphosphoglucuronate 
glucuronosyltransferase (UGT1A1) causing 
Crigler–Najjar and Gilbert syndromes: correlation 
Muhammad Ricky Ramadhian | Inherited Variation in Drugs Effect Independent in Pharmacokinetic 
JUKE | Volume 4 Nomor 8 | September 2014                                                                                                                      267 
of genotype to phenotype. Human Mutation. 
2000; 16(4): 297–306. 
21. Monaghan G, Ryan M, Seddon R, Hume R, 
Burchell B. Genetic variation in bilirubin UPD–
glucuronosyltransferase gene promoter and 
Gilbert's syndrome. Lancet. 1996; 
347(9001):578–81. 
22. Wasserman E, Myara A, Lokiec F, Goldwasser F, 
Trivin F, Mahjoubi M, et al. Severe CPT–11 
toxicity in patients with Gilbert's syndrome: two 
case reports. Annals of Oncology. 1997; 
8(10):1049–51. 
23. Guillemette C. Pharmacogenomics of human 
UDP–glucuronosyltransferase enzymes. The 
Pharmacogenomics Journal. 2003; 3(3):136–58. 
24. Habuchi O. Diversity and functions of 
glycosaminoglycan sulfotransferases. Biochim 
Biophys Acta. 2000; 1474(2):115–27. 
25. Senggunprai L, Yoshinari K, Yamazoe Y. Selective 
role of sulfotransferase 2A1 (SULT2A1) in the N-
sulfoconjugation of quinolone drugs in humans. 
Drug Metab Dispos. 2009; 37(8):1711–7. 
26. Strott C, 2002. Sulfonation and molecular action. 
Endocr Rev. 2002; 23(5):703–32. 
27. Strassburg CP, Strassburg A, Kneip S, Barut A, 
Tukey RH, Rodeck B, et al, 2002. Developmental 
aspects of human hepatic drug glucuronidation 
in young children and adults. Gut. 2002; 
50(2):259-65. 
28. Gilissen RA, Bamforth KJ, Stavenuiter JF, 
Coughtrie MW, Meerman JH. Sulfation of 
aromatic hydroxamic acids and hydroxylamines 
by multiple forms of human liver 
sulfotransferases. Carcinogenesis. 1994; 
15(1):39–45. 
29. Lindsay J, Wang LL, Li Y, Zhou SF. Structure, 
function and polymorphism of human cytosolic 
sulfotransferases. Current Drug Metabolism. 
2008; 9(2):99–105. 
30. Glatt H, Meinl W. Pharmacogenetics of soluble 
sulfotransferases (SULTs). Naunyn–
Schmiedeberg's Archives of Pharmacology. 2004; 
369(1):55–68. 
31. Arslan S, Silig Y, Pinarbasi H. An investigation of 
the relationship between SULT1A1 Arg(213)His 
polymorphism and lung cancer susceptibility in a 
Turkish population. Cell Biochemistry and 
Function, 2009; 27(4):211-5. 
32. Huang SK, Chiu AW, Pu YS, Huang YK, Chung CJ, 
Tsai HJ, et al. Arsenic methylation capability, 
myeloperoxidase and sulfotransferase genetic 
polymorphisms, and the stage and grade of 
urothelial carcinoma. Urologia Internationalis. 
2009; 82(2):227-34. 
33. Bardakci F, Arslan S, Bardakci S, Binatli AO, 
Budak M. Sulfotransferase 1A1 (SULT1A1) 
polymorphism and susceptibility to primary brain 
tumors. Journal of Cancer Research and Clinical 
Oncology. 2008; 134(1):109-14. 
34. Jakoby WB. The Glutathione S-transferases: A 
Group Of Multifunctional Detoxification 
Proteins. In: Meister A, eds. Advances in 
Enzymology and Related Areas of Molecular 
Biology Volume 46. New Jersey: John Wiley & 
Sons, Inc.; 2006. 
35. Gonzalez FJ, Tukey RH. Chapter III Drug 
metabolism. In: Brunton L, Lazo J, Parker K, eds. 
Goodmand & Gilman’s The Pharmacological 
Basis of Therapeutics. 11
th
 Edition. Philadelphia: 
McGraw Hill; 2006. 
36. Soboll S, Grundel S, Harris J, Kolb-Bachofen V, 
Ketterer B, Sies H. The content of glutathione 
and glutathione S-transferases and the 
glutathione peroxidase activity in rat liver nuclei 
determined by a non-aqueous technique of cell 
fractionation. Biochem J. 1995; 311(Pt 3):889-94. 
37. Morel F. Gene and protein characterization of 
the human glutathione S-transferase kappa and 
evidence for a peroxisomal localization. J Biol 
Chem. 2004; 279(16):16246–53. 
38. Sheehan D. Structure, function and evolution of 
glutathione transferases: implications for 
classification of non-mammalian members of an 
ancient enzyme superfamily. Biochem J. 2001; 
360(Pt 1):1-16. 
39. Armstrong R. Structure, catalytic mechanism, 
and evolution of the glutathione transferases. 
Chem Res Toxicol. 1997; 10(1):2–18. 
40. Van Bladeren P. Glutathione conjugation as a 
bioactivation reaction. Chem Biol Interact. 2000; 
129(1–2):61–76. 
41. Hayes J, Flanagan J, Jowsey I. Glutathione 
transferases. Annu Rev Pharmacol Toxicol 2005; 
45:51–88. 
42. Iida A SSSA, Harigae S, Osawa S, Mishima C, 
Kondo K, Kitamura Y, et al. Catalog of 46 single-
nucleotide polymorphisms (SNPs) in the 
microsomal glutathione S-transferase 1 (MGST1) 
gene. J Hum Genet. 2001; 46(10):590–4. 
43. Coleman MD. Conjugation and Transport 
Processes. In Human Drug Metabolism An 
Introduction Second Edition. New Jersey: Wiley 
& Sons, Ltd; 2010. 
44. Kawamura A GJ, Mushtaq A, Tsiftsoglou S, Vath 
G, Hanna P, Wagner C, et al. Eukaryotic 
arylamine N-acetyltransferase. Investigation of 
substrate specificity by high-throughput 
screening. Biochem Pharmacol. 2005; 69(2):347-
59. 
45. Grant D, Blum M, Beer M, Meyer U. 
Monomorphic and polymorphic human 
arylamine N-acetyltransferases: a comparison of 
liver isozymes and expressed products of two 
cloned genes. Mol Pharmacol. 1991; 39(2): 184–
Muhammad Ricky Ramadhian | Inherited Variation in Drugs Effect Independent in Pharmacokinetic 
JUKE | Volume 4 Nomor 8 | September 2014                                                                                                                      268 
91. 
46. Svensson CK, Hein DW. Phenotypic and 
Genotypic Characterization of N-Acetylation. In 
Lash LH, editor. Methods In Pharmacology And 
Toxicology:Drug Metabolism and Transport. 
Totowa: Humana Press; 2005. 
47. Brockton N, Little J, Sharp L. N–acetyltransferase 
polymorphisms and colorectal cancer: a HuGE 
review. American Journal of Epidemiology, 2000; 
151(9):846-61. 
48. Sim E, Stanley L, Gill EW, Jones A.. Metabolites of 
procainamide and practolol inhibit complement 
components C3 and C4. The Biochemical Journal. 
1998; 251(2):323–6. 
49. Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, et al. 
N–acetyltransferase 2 slow acetylator genotype 
associated with adverse effects of sulphasalazine 
in the treatment of inflammatory bowel disease. 
Canadian Journal of Gastroenterology. 2007; 
21(3): 155-8. 
50. Agúndez JA. Polymorphisms of human N–
acetyltransferases and cancer risk. Current Drug 
Metabolism. 2008; 9(6):520-31. 
51. Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH. 
Periconceptional multivitamin intake during 
early pregnancy, genetic variation of acetyl–N–
transferase 1 (NAT1), and risk for orofacial clefts. 
Birth Defects Resarch, Part A. Clinical and 
Molecular Teratology. 2004; 70(11): 846-52. 
52. Ladero J. Influence of polymorphic N–
acetyltransferases on non–
malignantspontaneous disorders and on 
response to drugs. Current Drug Metabolism. 
2008; 9(6):532–7. 
53. Gibson GG, Skett P. Introduction to Drug 
Metabolism. London: Nelson Thornes. 2001 
54. Miners JO, Mackenzie PI. Drug glucuronidation in 
humans. Pharmacology & Therapeutics. 1991; 
51(3):347–69. 
55. Patten, CJ. New technologies for assessing UDP-
glucuronosyl-transferase (UGT) metabolism in 
drug discovery and development. Drug Discov 
Today Tech. 2006; 3(1):73–8. 
56. Gregory PA, Lewinsky RH, Gardner-Stephen DA, 
Mackenzie PI. Regulation of UDP 
glucuronosyltransferases in the gastrointestinal 
tract. Toxicol Appl Pharmacol. 2004; 199(3):354-
63 
57. Tukey RH, Strassburg CP. Genetic multiplicity of 
the human UDP-glucuronosyltransferases and 
regulation in the gastrointestinal tract. Mol 
Pharmacol. 2001; 59(3):405–14. 
58. Cheng Z, Radominska-Pandya A, Tephly TR.. 
Studies on the sub-strate specificity of human 
intestinal UDP-glucuronosyltransferases 1A8 and 
1A10. Drug Metab Dispos. 1999;27(10):1165–70. 
59. King CD, Rios GR, Assouline JA, Tephly TR.. 
Expression of UDP-glucuronosyltransferases 
(UGTs) 2B7 and 1A6 in the human brain and 
identification of 5–hydroxytryptamine as a 
substrate. Archives of Biochemistry and 
Biophysics. 1999; 365(1):156-62 
 
